Logo

Mark Carbeau, Kenneth Kornman

Apr 07, 2015

Interleukin Genetics announced the appointment of Mark Carbeau as its new CEO and director. Carbeau will take over the CEO post from Kenneth Kornman, who has served as CEO and president since August 2012.

Carbeau was co-founder and CEO of Diagnostyx, a company focused on intelligent drug infusion systems. Before that, Carbeau was CEO of PolyRemedy, a company that aimed to improve wound healing outcomes by combining health IT and personalized therapeutics. Kornman will continue at Interleukin as president, chief scientific officer, and as a director.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.